Contribution: Industrial Research Assistance Program – Contributions to Firms
Resolvex Pharmaceuticals Inc.
$50,000.00
ADME, Efficacy, and Mechanism of Action Studies for Oral and Topical Formulations of RLV-102
EF 2018-19 · 2018-04-01
Résumé
This aim of this project is to determine the oral bioavailability and ADME properties of RLV-102 and develop a locally deliverable formulation (intestine/colon) for use as an oral therapeutic agent for inflammatory bowel disease.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Vancouver|Vancouver, British Columbia, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
757837729
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 151 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 151 jours.
Agreement End Date
2019-03-31
Agreement Number
904288
Agreement Start Date
2018-04-01
Agreement Title
ADME, Efficacy, and Mechanism of Action Studies for Oral and Topical Formulations of RLV-102
Agreement Title (French)
Études d'efficacité et de mécanisme d'action ADME pour les formulations orales et topiques de RLV-102
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Date
2018-10-22
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This aim of this project is to determine the oral bioavailability and ADME properties of RLV-102 and develop a locally deliverable formulation (intestine/colon) for use as an oral therapeutic agent for inflammatory bowel disease.
Description (French)
Études d'efficacité et de mécanisme d'action ADME pour les formulations orales et topiques de RLV-102
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Kingsway
Federal Riding (French)
Vancouver Kingsway
Federal Riding Number
59038
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
757837729
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Resolvex Pharmaceuticals Inc.
Recipient Postal Code
V5R 3Y2
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q3-904288
